Adjuvant Therapy Using Mistletoe Containing Drugs Boosts the T-Cell-Mediated Killing of Glioma Cells and Prolongs the Survival of Glioma Bearing Mice

  title={Adjuvant Therapy Using Mistletoe Containing Drugs Boosts the T-Cell-Mediated Killing of Glioma Cells and Prolongs the Survival of Glioma Bearing Mice},
  author={Sonja Sch{\"o}tterl and Stephan M Huber and Hans Lentzen and Michel Mittelbronn and Ulrike Naumann},
  journal={Evidence-based Complementary and Alternative Medicine : eCAM},
Viscum album L. extracts (VE) are applied as complementary cancer therapeutics for more than one century. Extracts contain several compounds like mistletoe lectins (ML) 1-3 and viscotoxins, but also several minor ingredients. Since ML-1 has been described as one of the main active components harboring antitumor activity, purified native or recombinant ML-1 has been also used in clinical trials in the last years. The present study examined and compared the immunoboosting effects of three ML-1… Expand
9 Citations
Mistletoe-Based Drugs Work in Synergy with Radio-Chemotherapy in the Treatment of Glioma In Vitro and In Vivo in Glioblastoma Bearing Mice
The results suggest that an adjuvant treatment of glioma patients with ML-containing drugs might be beneficial, and that ML containing drugs, if combined withglioma standard therapy, provide synergistic and additive anticancer effects. Expand
Mistletoe lectins: From interconnecting proteins to potential tumour inhibiting agents
This review aims at exploring the antitumor mechanisms of MLs against various cancer cell lines and mice animal models which encourages its application as effective bio-therapeutic tools to address range of human cancers. Expand
Immunocompetent Mouse Models in the Search for Effective Immunotherapy in Glioblastoma
The available knowledge concerning immune composition, stem cell characteristics and response to standard-of-care and immunotherapeutics for the most commonly available immunocompetent mouse models of GBM is summarized. Expand
Plant lectins in cancer therapeutics: Targeting apoptosis and autophagy-dependent cell death.
Although the application of plant lectins in cancer is still in very preliminary stage, advanced high-throughput technology could pave the way for the development of lectin-based complimentary medicine for cancer treatment. Expand
Plant-Derived Lectins as Potential Cancer Therapeutics and Diagnostic Tools
This review summarizes the current knowledge regarding the basis for the use of lectins in cancer diagnosis and therapy, providing a few examples of plant-derived carbohydrate-binding proteins with demonstrated antitumor effects. Expand
Engineering of Ribosome-inactivating Proteins for Improving Pharmacological Properties
This review focuses on the strategies used to improve the pharmacological properties of RIPs on human immunodeficiency virus (HIV) and cancers, and Coupling with polyethylene glycol (PEG) increases plasma time and reduces antigenicity. Expand
Effect of Ras-guanine nucleotide release factor 1-mediated H-Ras/ERK signaling pathway on glioma
Ras-GRF1 was upregulated in glioma tissues and correlated with its malignancy and prognosis, and Silencing Ras- GRF1, through mediating H-Ras/ERK pathway, may suppress the growth and metastasis ofglioma. Expand
Efficacy of mistletoe extract as a complement to standard treatment in advanced pancreatic cancer: study protocol for a multicentre, parallel group, double-blind, randomised, placebo-controlled clinical trial (MISTRAL)
This is the first placebo-controlled randomised trial assessing the impact of mistletoe extract as a complement to standard treatment on overall survival and health-related quality of life in patients with advanced pancreatic cancer. Expand


Viscum album neutralizes tumor-induced immunosuppression in a human in vitro cell model
A potential mode-of-action of VAE as an additive cancer therapy based on immunomodulatory effects is provided, however, the impact on the in vivo situation has to be evaluated in further studies. Expand
Recombinant mistletoe lectin induces p53-independent apoptosis in tumour cells and cooperates with ionising radiation
Recombinant mistletoe lectin alone and in combination with ionising radiation bypasses often prevalent apoptotic deficiencies in treatment-resistant tumour cells, including p53-mutated adenocarcinoma cells. Expand
Fermented Mistletoe Extract as a Multimodal Antitumoral Agent in Gliomas
In conclusion, ISCADOR Q, showing multiple positive effects in the treatment of glioblastoma, may be a candidate for concomitant treatment of this cancer. Expand
Suppression of growth of tumour cell lines in vitro and tumours in vivo by mistletoe lectins.
There is accumulating evidence that both types of MLs are able to induce an anti-angiogenic response in the host suggesting that the anti-metastatic effect observed on a series of tumour cell lines in mice is in part due to an inhibition of tumours-induced angiogenesis and in partDue to an induction of apoptosis. Expand
Low-dose mistletoe lectin-I reduces melanoma growth and spread in a scid mouse xenograft model
It is demonstrated that low-dose ML-I reduced melanoma growth and number of metastases in vivo, primarily due to immunomodulatory effects. Expand
Cytotoxic effects of mistletoe (Viscum album L.) in head and neck squamous cell carcinoma cell lines.
It was concluded that VA extracts have a cytotoxic effect on S CC9 and SCC25 cell lines, but while SCC9 cell line was more resistant to the action of the drugs, Iscador Qu Spezial and Iscadore M have higher cytotoxicity potential in both cell lines compared to IsCador P. Expand
[Effect of mistletoe lectin therapy on serum level of defined serum proteins (acute phase proteins) in tumor patients].
The increase of acute phase reactants after administration of ML-1 correlates positively with the activity of lymphatic cells in FACS (fluorescence-activated cell sorter) staining experiments and indicates the immunoreactive potency of this substance which may be speculated to be cytokine-induced. Expand
Nitric oxide involvement in the anti-tumor effect of mistletoe (Viscum album L.) extracts Iscador on human macrophages.
VA-M and VA-P were able to increase anti-tumoral activity of activated human macrophages, with a possible role for nitric oxide in this effect. Expand
Anti-mistletoe lectin antibodies are produced in patients during therapy with an aqueous mistletoe extract derived fromViscum album L. and neutralize lectin-induced cytotoxicity in vitro
It is questionable whether exposing tumor cells to mistletoe extracts in vivo exerts the same direct effect on tumor cells that is observed in vitro. Expand
Viscumins functionally modulate cell motility-associated gene expression.
ML containing compounds might provide clinical benefit as adjuvant therapeutics in the treatment of patients with invasively growing tumors such as glioblastomas because of the regulation of motility associated gene expression. Expand